IGE025A_XOLAIR _RESPIRATORY: payments to doctors
Payments that named IGE025A_XOLAIR _RESPIRATORY as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $33K
- Providers
- 5
- Transactions
- 16
- Average per transaction
- $2,042
The per-transaction average — $2,042 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 5 providers the average total is $6,536, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novartis Pharma AG | $32,679 | 100.0% |